Related Experiment Video
Updated: Dec 1, 2025

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
[Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase
Dietrich Hüppe1, Claus Niederau2, Yvonne Serfert3
1Gastroenterologische Gemeinschaftspraxis Herne, Herne, Deutschland.
Insights
The COVID-19 pandemic disrupted chronic hepatitis C care in Germany, with reduced consultations and antiviral treatments. Delayed diagnoses of liver decompensation and cancer raise significant concerns despite most centers reporting no long-term issues.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- The COVID-19 pandemic imposed unprecedented challenges on healthcare systems globally.
- Lockdown regulations significantly impacted routine medical services, including those for chronic conditions.
Purpose of the Study:
- To analyze the influence of the COVID-19 pandemic on the healthcare of patients with chronic hepatitis C in Germany.
- To assess the impact of pandemic-related disruptions on diagnosis, therapy, and monitoring of hepatitis C patients.
Main Methods:
- A structured online questionnaire survey was distributed to centers participating in the German Hepatitis C-Registry (DHC-R).
- Data were collected from 64 centers regarding consultation changes, patient-initiated cancellations, telehealth adoption, and treatment modifications between March and May 2020.
Main Results:
- 11% of centers stopped regular consultations, and 58% reduced them during lockdown; over 50% of cancellations were patient-initiated.
- New antiviral treatments decreased significantly compared to 2019, while telehealth options like telephone and video consultations were introduced.
- Delayed diagnoses of liver decompensation (22%) and hepatocellular carcinoma (9.4%) were reported, alongside concerns about personal protective equipment availability (56%).
Conclusions:
- Diagnosis, therapy, and monitoring for chronic hepatitis C patients were negatively affected during the COVID-19 pandemic.
- While most centers anticipate no medium-to-long-term healthcare problems, delayed diagnoses of potentially fatal liver decompensations are a major concern.
- The study highlights the need for resilient healthcare strategies to ensure continuous care for chronic conditions during public health crises.
Background:
Healthcare services were faced with unprecedented challenges due to the COVID-19 pandemic and its associated lockdown regulations. In order to analyse the influence of the pandemic on the healthcare of patients with chronic hepatitis C in Germany, we carried out a structured questionnaire among all centres participating in the German Hepatitis C-Registry (DHC-R).
Methods:
320 centres of the DHC-R were invited to participate in an online survey. Of these, 74 centres had included ≥ 5 patients in the last 12 months.
Findings:
A fully answered questionnaire was sent back by 64 centres. Due to the lockdown regulations, 11 % of the centres had stopped their regular consultation between March and May 2020; 58 % had reduced the consultations and 32 % did not change the consultations. More than 50 % of the appointment cancellations were done by the patients. 52 % of the centres offered a new or additional telephone consultation and 17 % offered a new video consultation. Between March and May 2020, the number of patients newly treated with antivirals was markedly lower when compared with the same period in 2019. All centres had returned to their usual consultation procedures in July 2020. Almost 80 % indicated that there were no significant limitations in patient's healthcare. However, 22 % of the centres stated that liver decompensation was diagnosed late and 9.4 % stated that diagnosis of hepatocellular carcinoma was delayed. An adequate amount of personal protective equipment (including disinfectants) was available in 56 % of the centres. Official information by public healthcare authorities was considered sufficient by 63 % of the centres.
Summary:
Diagnosis, therapy and monitoring of patients with chronic hepatitis C were impaired during the COVID-19 pandemic. Nevertheless, the majority of the centres did not see healthcare problems for these patients in the medium and long term. However, the fact that the diagnosis of liver decompensations with potential lethal consequences was delayed in a considerable number of patients causes major concern.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Retrovirus Life Cycles
Myocarditis III: Medical Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

